Pulse Biosciences has announced the appointment of David Kenigsberg (Florida Heart Rhythm Specialists, Fort Lauderdale, USA) as chief medical officer (CMO) of Electrophysiology. In addition, Andrea Natale (St David’s Medical Center, Austin, USA) will become a medical advisor for the company, joining existing advisors Vivek Reddy and Jacob Koruth (both Mount Sinai Health System, New York, USA) who—together—will continue to support development and clinical efforts behind Pulse Biosciences’ nano-pulsed field ablation (PFA) 360 cardiac catheter.
“I am inspired by the potential of nano-PFA and the unique catheter design of the 360 catheter that is already demonstrating the ability to isolate pulmonary veins with ease and speed,” said Kenigsberg. “I was impressed when I saw the 360 catheter in use and am excited to work with Pulse to deliver robust clinical data with the 360—which I believe will substantially advance the treatment of atrial fibrillation [AF]. I look forward to supporting this team through its next phase of clinical development.”
Kenigsberg is a practising cardiac electrophysiologist, and he is also the founder of Florida Heart Rhythm Specialists and the Fort Lauderdale Heart and Rhythm Surgical Center. He has been the medical director of the Electrophysiology Lab at HCA Westside Medical Center (Plantation, USA) since 2007. In addition, he has published numerous scholarly articles in peer-reviewed medical journals, and has advised in the development of and has been the primary investigator/co-investigator in many clinical trials involving ablation tools. Kenigsberg is a fellow of the American College of Cardiology (ACC) and the Heart Rhythm Society (HRS). He is also the president of the Florida Chapter of the ACC and sits on the ACC board of governors.
“This is an exciting time in electrophysiology, as pulsed field ablation technologies are becoming widely adopted and advancing the standard of care,” Natale stated. “I am excited to support the Pulse team in the clinical efforts for the 360 catheter.”
Natale is the executive medical director of the Texas Cardiac Arrhythmia Institute at St David’s Medical Center, and the national medical director of Cardiac Electrophysiology for HCA Healthcare. A dedicated researcher and pioneer, Natale focuses on innovative advances in the treatment of AF. He has been and continues to be involved in many first-in-human trials to test investigational devices, recently performing the first preclinical and clinical studies to develop and perfect ablation catheters utilising a novel, groundbreaking ablation energy source known as irreversible electroporation.
“We are significantly strengthening our team with the addition of these renowned physicians, who will contribute to generating high-quality clinical data that demonstrates the clinical performance profile of the 360 catheter,” said Burke Barrett, president and chief executive officer (CEO) of Pulse Biosciences. “I want to thank Drs Reddy and Koruth for their significant contributions in the preclinical and clinical evaluations of the 360 catheter to date.”
